^“FDA approves Zytiga for late-stage prostate cancer” (プレスリリース), Food and Drug Administration (FDA), (2011年4月28日), http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.htm
^ abJ&J Expands Options For Prostate Cancer, Investor's Business Daily, 24 September 2010
^Attard G, Belldegrun AS, de Bono JS (December 2005). “Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer”. BJU Int.96 (9): 1241–6. doi:10.1111/j.1464-410X.2005.05821.x. PMID 16287438.
^ abc“Zytiga (abiraterone) dosing, indications, interactions, adverse effects, and more”. Medscape Reference. WebMD. 2014年1月24日閲覧。
^“ザイティガ錠250mg 添付文書” (2015年11月). 2016年6月30日閲覧。
^“Zytiga prescribing information (pdf)”. Janssen Biotech (2012年5月). 2012年5月19日閲覧。
^Scowcroft H (2011年9月21日). “Where did abiraterone come from?”. Cancer Research UK. 2011年9月28日閲覧。
^“A new way to treat prostate cancer: The story of abiraterone”. The Institute of Cancer Research (2012年9月10日). 2012年11月12日閲覧。
^O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M (June 2004). “Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer”. Br. J. Cancer90 (12): 2317–25. doi:10.1038/sj.bjc.6601879. PMC: 2409523. PMID 15150570. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409523/.
^Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008). “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven”. Journal of Clinical Oncology26 (28): 4563–71. doi:10.1200/JCO.2007.15.9749. PMID 18645193.
^Cole A (2008). “Cancer expert doubts claims about prostate cancer trial”. BMJ337: a979. doi:10.1136/bmj.a979. PMID 18653636.
^Attard G, Reid AH, Dearnaley D, De Bono JS (2008). “New prostate cancer drug: Prostate cancer's day in the sun”. BMJ337: a1249. doi:10.1136/bmj.a1249. PMID 18694888.
^“Hormone inhibitor promising for hard-to-treat prostate cancer” (プレスリリース), European Society for Medical Oncology, (2007年7月8日), オリジナルの2008年6月13日時点によるアーカイブ。, http://www.esmo.org/news/?news_id=972008年7月22日閲覧。
^Warry, Richard (2008年7月21日). “Drug for deadly prostate cancer”. BBC News Online. オリジナルの2008年8月30日時点によるアーカイブ。. http://web.archive.org/web/20080830221552/http://news.bbc.co.uk/2/hi/health/7502238.stm2008年8月20日閲覧。
^“CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer”. Br. J. Cancer100 (5): 671–5. (March 2009). doi:10.1038/sj.bjc.6604904. PMC: 2653756. PMID 19223900. https://doi.org/10.1038/sj.bjc.6604904.
^“Phase II results demonstrate efficacy of abiraterone acetate plus prednisone for castration-resistant prostate cancer”. ecancermedicalscience (2010年2月17日). 2014年11月13日閲覧。
^ ab“BTG and Ortho Biotech's Prostate Cancer Trial Unblinded”. Genetic Engineering & Biotechnology News (2010年9月10日). 2011年5月26日閲覧。
^CRUKD/08/044 A CR-UK Phase I/II trial of abiraterone acetate in patients with ER+, PR+ or AR+ refractory metastatic breast cancer : Cancer Research UK
^Andrew Pollack (2012年5月17日). “Trial Supports Earlier Use of a Prostate Cancer Drug”. The New York Times. http://www.nytimes.com/2012/05/17/health/zytiga-a-prostate-cancer-drug-does-well-in-trial.html. "A new drug used to treat advanced prostate cancer may also help men if used early in the course of the disease, before an operation, researchers reported Wednesday. In a small clinical trial, six months of treatment with the drug, Johnson & Johnson's Zytiga, added to standard therapy, eliminated or nearly eliminated tumors in about one-third of men whose disease had not yet spread beyond the prostate gland but was considered likely to do so."
^Jennifer Corbett Dooren; Peter Loftus (2012年5月16日). “Study: J&J's Zytiga Can Eliminate Some Prostate Tumors”. The Wall Street Journal. http://online.wsj.com/article/SB10001424052702303360504577408700087593244.html
^“ZYTIGA (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting” (プレスリリース), Janssen Research & Development, (2012年5月18日), http://www.drugs.com/clinical_trials/zytiga-abiraterone-acetate-data-presented-2012-american-society-clinical-oncology-asco-annual-13565.html
^“NCT00638690”. ClinicalTrials.gov. 2008年8月21日時点のオリジナルよりアーカイブ。2008年8月22日閲覧。 “Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy”
^“NCT00887198”. ClinicalTrials.gov. 2009年12月29日閲覧。 “Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer”
^Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (December 2012). “Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy”. N. Engl. J. Med.368 (2): 138–48. doi:10.1056/NEJMoa1209096. PMC: 3683570. PMID 23228172. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683570/.
^“FDA Approval for Abiraterone Acetate”. 2014年11月13日閲覧。
外部リンク
ザイティガ 製品情報サイト
FDAが進行前立腺癌治療薬アビラテロンの適応を拡大承認
"Full Prescribing Information". May 2014.
"Zytiga (abiraterone acetate) tablet". U.S. Daily Med.
"Patient Information". Janssen Biotech. May 2012.
"Full Product Information". Janssen Biotech. April 2012.
"Prescribing Information". Janssen Biotech. May 2012.
"Mechanism of Action"
"Coadministration with Prednisone"
"Dosage & Administration Guide"
Information about abiraterone for UK patients – Cancer Research UK's CancerHelp UK website
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
…combining abiraterone with enzalutamide. There are only limited data on the activity of enzalutamide in patients who have previously been treated with abiraterone and on the activity of abiraterone after …
…combining ADT with abiraterone is based upon the ability of abiraterone to block this conversion. Two large randomized clinical trials have demonstrated that the combination of abiraterone plus ADT significantly …
…randomly assigned to either abiraterone plus prednisone alone or abiraterone plus prednisone and continued enzalutamide . Progression-free survival was 5.7 months with abiraterone plus enzalutamide and 5.6 …
…hormone-sensitive prostate cancer receiving abiraterone in addition to ADT . Of note, in the LATITUDE (Long-Acting Therapy to Improve Treatment Success in Daily Life) study of abiraterone, approximately 20 percent of …
…combining ADT with abiraterone is based upon the ability of abiraterone to block this conversion. Two large randomized clinical trials have demonstrated that the combination of abiraterone plus ADT significantly …
アビラテロン酢酸エステルは生体内で速やかにアビラテロンへ加水分解され、アンドロゲン合成酵素である17α-hydroxylase/C17,20-lyase(CYP17)活性を阻害する。 In vitroにおいて、アビラテロンはヒト副腎皮質由来腫瘍細胞株(NCI-H295R)におけるテストステロンの合成を阻害した。マウス及びラットにおいてアビラテロン酢酸エステル(反復腹腔内又は経口投与)は血漿中テストステロン濃度を低下させた。